This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, organic revenue growth, diluted EPS, free cash flow, and leverage; the Company's execution on its brand-building strategy; the Company's expected growth; and the Company's capital allocation strategy, including its focus on reducing debt. Words such as "anticipate," "continue," "positioned," "will," "expect," "project," "may," "should," "could," "would," and similar expressions identify forward-looking statements. Such forward-looking statements represent the Company's expectations and beliefs and involve a number of known and unknown risks, uncertainties and other
factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, the impact of geopolitical instability, including on economic and business conditions; consumer trends; disruptions to manufacturing, distribution and supply chain and related price increases; labor shortages; competitive pressures; the impact of the Company's advertising and promotional and new product development initiatives; customer inventory management initiatives; the ability to pass along rising costs to customers without impacting sales; fluctuating foreign exchange rates; and other risks set forth in Part I, Item 1A. Risk Factors in the Company's Annual Report on Form 10-K for the year ended March 31, 2023. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation. Except to the extent required by applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether as a result of new information, future events, or otherwise.
All adjusted GAAP numbers presented are footnoted and reconciled to their closest GAAP measurement in the attached reconciliation schedule or in our August 3, 2023 earnings release in the "About Non-GAAP Financial Measures" section.
F I R S T Q U A R T E R F Y 2 4 R E S U L T S
Agenda for Today's Discussion
Performance Update II. Financial Overview III. FY 24 Outlook
F I R S T Q U A R T E R F Y 2 4 R E S U L T S
3
Performance Update
F I R S T Q U A R T E R F Y 2 4 R E S U L T S
Business Momentum Continued in First Quarter FY 24
Q1 FY 24 Sales
Drivers
Superior Earnings
and FCF
Disciplined Capital
Allocation
Solid quarterly Revenue of $279.3 million, up 1.8% vs. PY organically(1)
Continued strong performance enabled by benefits of leading & diversified portfolio
Continue to execute proven brand-building strategy
Gross Margin improved sequentially
Continued consistent EBITDA margin(2)
Solid financial profile and resulting Free Cash Flow(2) generation
Completed $25MM share repurchase authorization
Debt reduction remains a key part of capital allocation strategy
Continued focus on disciplined capital allocation resulting in leverage of 3.2x(3)
F I R S T Q U A R T E R F Y 2 4 R E S U L T S
5
Attachments
Original Link
Original Document
Permalink
Disclaimer
Prestige Consumer Healthcare Inc. published this content on 03 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 August 2023 11:44:00 UTC.
Prestige Consumer Healthcare Inc. is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club and e-commerce stores in North America (the United States and Canada) and in Australia and certain other international markets. The Company operates through two segments: North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands include Monistat and Summerâs Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart treatments, Little Remedies pediatric over-the-counter products, Boudreauxâs Butt Paste diaper rash ointments, Nix lice treatment, Debrox earwax remover, and others.